According to the Complaint, Immunomedics purports to be a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.